Key takeaways
Tenofovir disoproxil fumarate (Viread) and Triumeq (abacavir/dolutegravir/lamivudine) are both medications used to treat human immunodeficiency virus (HIV) infections. However, they belong to different drug classes and have distinct characteristics. Viread is a nucleoside reverse transcriptase inhibitor (NRTI) that is also approved for treating chronic hepatitis B virus (HBV) infections, while Triumeq is a combination of three antiretrovirals: abacavir and lamivudine (both NRTIs) and dolutegravir (an integrase inhibitor). Viread must be taken with other HIV antiretrovirals for the treatment of HIV. Viread is available as a tablet and a powder for oral use, whereas Triumeq comes as a tablet and a dissolvable tablet for oral suspension. Viread is available as a generic, making it a lower-cost option, while Triumeq is brand only. Triumeq requires a genetic test before starting due to the risk of a serious allergic reaction. Common side effects of Viread include rash, diarrhea, and headache, while Triumeq can cause higher lipase levels and trouble sleeping. Both medications require careful monitoring for liver and kidney health, but Triumeq has more drug interactions, including with antacids and certain seizure medications.
